Neureiter daniel (3 Ergebnisse)

Hardcover/Pappeinband. Zustand: Sehr gut. 200 S. : 50 col. Ill. Sehr guter Zustand. In Folie verschweißt. Very good. Shrink wrapped. Sprache: Englisch Gewicht in Gramm: 1400.

Zustand: New. In.

Zustand: Wie neu. 1. Ed. 200 S. : 50 farb. Ill. Sehr gutes Ex. - This book comprises an in-depth view on the current knowledge of chronic clonal myeloid diseases. Special emphasis is laid on chronic myeloid leukemia and "classic" myeloproliferative disorders (essential thrombocythemia, polycythemia vera, primary myelofibrosis) as well as myelodysplastic syndromes, oligoblastic leukemias, paroxysmal nocturnal hemoglobinuria and overlap diseases. Both young physicians in hematological training as well as practicing hematologists are addressed, with the aim of imparting a clear understanding of these disorders. In-depth information on the most relevant cell-biological pathways is accentuated by graphics. Guidelines for diagnosis, complemented by cytological, histological and clinical photos, as well as easy-to-follow algorithms with clinical as well as laboratory findings are provided. Current management of routine as well as precarious clinical situations are discussed and supplemented with boxes highlighting the most relevant information in keywords. // Introduction to "Classic" Chronic Myeloproliferative Disorders (CMPDs) - - Molecular and Cellular Biology - Lisa Pleyer and Richard Greil / - Pathogenetic Role of the JAK2VS17F Mutation -Definition of JAK2V617F+ CMPDs with Common Pathogenesis and Natural Disease Evolution from ET to PV to post-ETYPV-MF vs JAK2V617F" CMPDs - The Clonal Stem Cell Nature of "Classic CMPDs" - JAK2V617F is an Acquired Somatic Mutation - Timing of the JAK2 Mutation - Relationship Between its Emergence and Clonal Hematopoiesis: JAK2V617F is an Early, but not the Earliest Event in the Transformation Process - JAK2 Mutations in Murine Systems - Disease Phenotype and Biologic Consequences - Gene Dosage and the Role of JAK2 Mutations - in the Generation of Different Types of CMPD - JAK2-Mutations, Signaling Aberrations and Consequences for Cell Biology - Altered Downstream JAK2 Signaling and STAT-Phosphorlyation States for the Discrimination Between Classic CMPD Entities - Other Important (Epi)genetic Factors Functionally - Equivalent to the JAK2V617F Mutation - Therapeutic Targeting of the JAK2-STAT Signaling Axis - Essential Thrombocythemia (ET) - Lisa Pleyer, Victoria Faber, Daniel Neureiter, and Richard Greil - Epidemiology of ET - Course of Disease and Prognosis of ET - Cellular and Biological Abnormalities Observed - in ET - Monoclonality Versus Polyclonality in ET - Endogenous Megakaryocytic Colony (EMC) Formation and Endogenous Erythroid - Colony (EEC) Formation - Overexpression of the PRV-1 Gene - Decreased cMPL-Expression and Elevated Serum Thrombopoietin (TPO) Levels - Quantitative and Qualitative Defects in Platelets and Leukocyte Biology in ET (and PV) Relevance of Periodic Platelet Apheresis in Pregnancy - Recommendations for Treatment of Pregnant Women with ET - Childhood ET - Familial, Hereditary Thrombocytosis - Rare ET Varients - Philadelphia Chromosome (Ph)-Positive ET - Bcr-Abl Positive Ph-Negative ET - Polycythemia Vera (PV) - Lisa Pleyer, Daniel Neureiter, and Richard Greil - Epidemiology of PV - Should ET and PV be Considered as the Same - Disease? - Pathophysiology and Molecular Biology of PV - Overview of the Role of JAK2V617F Mutations inPV - Overexpression of the PRV-1 Gene in PV - Other Molecular Features Implicated in the Pathogenesis of PV - Exon 12 Mutations in JAK2VS17F Negative PV - Single Nucleotide Polymorphisms (SNPs) in JAK2 and EPO-R - Contribution of Host Genetic Variation to CMPD Phenotype - Cytogenetics in PV - Clinical Features and Symptoms Occurring in PV - Disease Complications - Diagnosis of Polycythemia Vera (PV) - Differential Diagnosis of Polycythemia Vera - Absolute Polycythemia/Erythrocytosis - Relative and Spurious/Apparent Polyglobulia - Idiopathic Erythrocytosis (IE) - Risk Stratification of Patients with PV - Treatment of PV - Phlebotomy - Antiaggregatory Therapy - Indications for Treatment and Choice - of Cytoreductive Drugs in Patients with PV - Hydroxyurea - Interferon-a - P.…